Trial · NCT06004037
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | semi-quantitative scale (SQS) change versus baseline | 12 weeks | The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load. |
| Secondary | Change from baseline in SQS | 4 weeks and 8 weeks | The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load. |
| Secondary | Sputum culture conversion rate | 12 weeks | neg culture x3( sputum conversion) |
| Secondary | Time to culture conversion | 12 weeks | from the date of assignment to the first negative result. |
| Secondary | Time to positivity in the liquid culture automated system (MGIT) | 12 weeks | time to detection of positive in MGIT system |
| Secondary | Negative sputum culture rate at each time point after baseline | 12 weeks | negative culture results in MGIT and solid media |
| Secondary | Change from baseline in the inflammatory marker | 12 weeks | erythrocyte sedimentation rate \[ESR\]) at each time point |
| Secondary | Change from baseline in the CT score | 12 weeks | The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. Descriptive statistics for each point in time are presented, and intra-group comparison of CT score changes at 12 weeks compared to baseline |
| Secondary | Quality of Life Questionnaire-Bronchiectasis | 12 weeks | The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. |
| Secondary | Six-minute walk test | 12 weeks | Six-minute walk test |
| Secondary | Extended administration | After 12 weeks | 1\) SQS at each time point compared to baseline in subjects receiving extended administration * The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load 2) Inflammatory markers at each time point compared to baseline in subjects receiving extended administration * erythrocyte sedimentation rate 3) CT scores at each time point compared to baseline in subjects receiving extended administration * The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. 4\) QOL-B change at each time point compared to baseline in subjects receiving extended administration * The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. 5\) sputum culture negative conversion at each time point compared to baseline in subjects receiving extended administration * negative culture results in MGIT and solid media |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06004037/registered